Screener
Immunovant, Inc. IMVT CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | Years Ended March 31, 2026 | Years Ended March 31, 2025 | Years Ended March 31, 2024 |
|---|---|---|---|
| Due to Roivant Sciences Ltd. | (98) | 255 | (329) |
| Net cash used in operating activities | (407,310) | (375,874) | (214,227) |
| Cash flows from investing activities | |||
| Purchases of property and equipment | (8) | (759) | (360) |
| Net cash used in investing activities | (8) | (759) | (360) |
| Cash flows from financing activities | |||
| Proceeds from issuance of common stock upon underwritten offering, net of underwriter discounts and commissions, and private placement | 544,194 | 450,000 | 472,745 |
| Payment of offering and private placement costs | (504) | (319) | (6,012) |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s capex?
- Immunovant, Inc. (IMVT) reported capex of $8K in Q1 2026.
- How has Immunovant, Inc.'s capex changed year-over-year?
- Immunovant, Inc.'s capex decreased by 96.0% year-over-year, from $201K to $8K.
- What is the long-term trend for Immunovant, Inc.'s capex?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s capex has grown at a -57.9% compound annual growth rate (CAGR), from $254K to $8K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Immunovant, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude